#DiabetesManagement #HeartHealth #HealthyLifestyle
hsph.harvard.edu
GLP-1 drugs combined with healthy lifestyle habits linked with reduced cardiovascular risk among diabetes patients | Harvard T.H. Chan School of Public Health
Boston, MA -- Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy lifestyle habits, according to a new study led by researchers at Harvard T.
#Diabetes #WeightLoss #MedicalResearch
www.yahoo.com
Researchers discover new benefit of once-a-day weight loss pill
Add Yahoo as a preferred source to see more of our stories on Google.
Researchers have hailed the results of a new study on a once-a-day weight loss pill as an "important advancement" in type 2 diabetes care.
#GLP1 #WeightLoss #DiabetesManagement
www.businessinsider.com
Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch.
The pill, which analysts say might cost $300 a month, could be available as soon as mid-2026.
Better injections and better pills.
#Pharmaceuticals #WeightLoss #DiabetesMedication
us.cnn.com
Novo Nordisk to slash Ozempic and Wegovy list prices by up to 50% for 2027 | CNN
Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and Rybelsus by up to half starting in 2027.
#WeightLoss #DiabetesTreatment #GLP1
nypost.com
People dropped out of Eli Lilly's new GLP-1 drug trial because they...
Participants taking the highest dose of Eli Lilly's new GLP-1 drug lost an average of 28. 7% of their body weight in a late-stage trial, putting it on track to be a heavyweight in the crowded world of weight-loss and diabetes treatments.
#Diabetes #VisionHealth #Metformin
www.foxnews.com
Common diabetes drug may help preserve eyesight as people age
A common medication for diabetes may slow down age-related vision loss, according to new research.
People with diabetes who were over the age of 55 and taking metformin -- a prescription drug most commonly used to treat type 2 diabetes -- were 37% less likely to develop intermediate age-related macular degeneration (AMD) over five years compared to those not taking it.
